NWRN Stock Overview
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States.
Newron Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CHF1.35|
|52 Week High||CHF2.75|
|52 Week Low||CHF1.20|
|1 Month Change||3.85%|
|3 Month Change||-6.90%|
|1 Year Change||-42.31%|
|3 Year Change||-78.81%|
|5 Year Change||-93.79%|
|Change since IPO||-97.46%|
Recent News & Updates
We Think Newron Pharmaceuticals (VTX:NWRN) Has A Fair Chunk Of Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|NWRN||CH Pharmaceuticals||CH Market|
Return vs Industry: NWRN underperformed the Swiss Pharmaceuticals industry which returned 19% over the past year.
Return vs Market: NWRN underperformed the Swiss Market which returned -2.1% over the past year.
|NWRN Average Weekly Movement||9.8%|
|Pharmaceuticals Industry Average Movement||6.3%|
|Market Average Movement||4.9%|
|10% most volatile stocks in CH Market||8.6%|
|10% least volatile stocks in CH Market||2.5%|
Stable Share Price: NWRN is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: NWRN's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson’s disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain.
Newron Pharmaceuticals Fundamentals Summary
|NWRN fundamental statistics|
Is NWRN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NWRN income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 15, 2022
|Earnings per share (EPS)||-0.83|
|Net Profit Margin||-258.61%|
How did NWRN perform over the long term?See historical performance and comparison
Is Newron Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: NWRN (CHF1.35) is trading below our estimate of fair value (CHF91.67)
Significantly Below Fair Value: NWRN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: NWRN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Pharmaceuticals industry average.
PE vs Market: NWRN is unprofitable, so we can't compare its Price-To-Earnings Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NWRN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NWRN is overvalued based on its Price-To-Book Ratio (7.5x) compared to the XE Pharmaceuticals industry average (2.5x).
How is Newron Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NWRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).
Earnings vs Market: NWRN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NWRN's is expected to become profitable in the next 3 years.
Revenue vs Market: NWRN's revenue (40.3% per year) is forecast to grow faster than the Swiss market (4.3% per year).
High Growth Revenue: NWRN's revenue (40.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NWRN's Return on Equity is forecast to be very high in 3 years time (2637.5%).
How has Newron Pharmaceuticals performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NWRN is currently unprofitable.
Growing Profit Margin: NWRN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NWRN is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare NWRN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NWRN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (14.9%).
Return on Equity
High ROE: NWRN has a negative Return on Equity (-479.59%), as it is currently unprofitable.
How is Newron Pharmaceuticals's financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NWRN's short term assets (€39.4M) exceed its short term liabilities (€3.7M).
Long Term Liabilities: NWRN's short term assets (€39.4M) do not cover its long term liabilities (€43.7M).
Debt to Equity History and Analysis
Debt Level: NWRN's net debt to equity ratio (255.8%) is considered high.
Reducing Debt: NWRN's debt to equity ratio has increased from 0.7% to 1369.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NWRN has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if NWRN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Newron Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NWRN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NWRN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NWRN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NWRN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NWRN has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Stefan Weber (56 yo)
Mr. Stefan Weber serves as the Chief Financial Officer and Finances and Administration Director at Duktus S.A. Mr. Weber has been the Chief Executive Officer of Newron Pharmaceuticals SpA since June 1, 201...
CEO Compensation Analysis
Compensation vs Market: Stefan's total compensation ($USD544.58K) is about average for companies of similar size in the Swiss market ($USD491.72K).
Compensation vs Earnings: Stefan's compensation has been consistent with company performance over the past year.
Experienced Management: NWRN's management team is seasoned and experienced (9.9 years average tenure).
Experienced Board: NWRN's board of directors are seasoned and experienced ( 10.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Newron Pharmaceuticals S.p.A.'s employee growth, exchange listings and data sources
- Name: Newron Pharmaceuticals S.p.A.
- Ticker: NWRN
- Exchange: SWX
- Founded: 1999
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CHF24.091m
- Shares outstanding: 17.85m
- Website: https://www.newron.com
Number of Employees
- Newron Pharmaceuticals S.p.A.
- Via Antonio Meucci 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/25 00:00|
|End of Day Share Price||2022/05/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.